| Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial S McCormack, DT Dunn, M Desai, DI Dolling, M Gafos, R Gilson, ... The Lancet 387 (10013), 53-60, 2016 | 2086 | 2016 |
| Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition J Goodall, J Mateo, W Yuan, H Mossop, N Porta, S Miranda, ... Cancer discovery 7 (9), 1006-1017, 2017 | 387 | 2017 |
| Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial A Birtle, M Johnson, J Chester, R Jones, D Dolling, RT Bryan, C Harris, ... The Lancet 395 (10232), 1268-1277, 2020 | 368 | 2020 |
| Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer A Paschalis, B Sheehan, R Riisnaes, DN Rodrigues, B Gurel, C Bertan, ... European urology 76 (4), 469-478, 2019 | 339 | 2019 |
| Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer A Sharp, I Coleman, W Yuan, C Sprenger, D Dolling, DN Rodrigues, ... The Journal of clinical investigation 129 (1), 192-208, 2019 | 332 | 2019 |
| IL-23 secreted by myeloid cells drives castration-resistant prostate cancer A Calcinotto, C Spataro, E Zagato, D Di Mitri, V Gil, M Crespo, ... Nature 559 (7714), 363-369, 2018 | 315 | 2018 |
| Genomics of lethal prostate cancer at diagnosis and castration resistance J Mateo, G Seed, C Bertan, P Rescigno, D Dolling, I Figueiredo, ... The Journal of clinical investigation 130 (4), 1743-1751, 2020 | 225 | 2020 |
| Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer DN Rodrigues, P Rescigno, D Liu, W Yuan, S Carreira, MB Lambros, ... The Journal of clinical investigation 128 (10), 4441-4453, 2018 | 204 | 2018 |
| Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. S Johnston, S Puhalla, D Wheatley, A Ring, P Barry, C Holcombe, ... AMER SOC CLINICAL ONCOLOGY, 2019 | 178 | 2019 |
| SPOP-mutated/CHD1-deleted lethal prostate cancer and abiraterone sensitivity G Boysen, DN Rodrigues, P Rescigno, G Seed, D Dolling, R Riisnaes, ... Clinical cancer research 24 (22), 5585-5593, 2018 | 141 | 2018 |
| BRD4 promotes DNA repair and mediates the formation of TMPRSS2-ERG gene rearrangements in prostate cancer X Li, GH Baek, SG Ramanand, A Sharp, Y Gao, W Yuan, J Welti, ... Cell reports 22 (3), 796-808, 2018 | 134 | 2018 |
| Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC) J Welti, A Sharp, W Yuan, D Dolling, D Nava Rodrigues, I Figueiredo, ... Clinical Cancer Research 24 (13), 3149-3162, 2018 | 131 | 2018 |
| Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study J Mateo, HH Cheng, H Beltran, D Dolling, W Xu, CC Pritchard, H Mossop, ... European urology 73 (5), 687-693, 2018 | 118 | 2018 |
| Plasma cell-free DNA concentration and outcomes from taxane therapy in metastatic castration-resistant prostate cancer from two phase III trials (FIRSTANA and PROSELICA) N Mehra, D Dolling, S Sumanasuriya, R Christova, L Pope, S Carreira, ... European urology 74 (3), 283-291, 2018 | 104 | 2018 |
| Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions S Hué, AE Brown, M Ragonnet-Cronin, SJ Lycett, DT Dunn, E Fearnhill, ... Aids 28 (13), 1967-1975, 2014 | 81 | 2014 |
| An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis DI Dolling, M Desai, A McOwan, R Gilson, A Clarke, M Fisher, G Schembri, ... Trials 17, 1-11, 2016 | 78 | 2016 |
| The context of sexual risk behaviour among men who have sex with men seeking PrEP, and the impact of PrEP on sexual behaviour M Gafos, R Horne, W Nutland, G Bell, C Rae, S Wayal, M Rayment, ... AIDS and Behavior 23, 1708-1720, 2019 | 72 | 2019 |
| Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts D Lorente, D Olmos, J Mateo, D Dolling, D Bianchini, G Seed, P Flohr, ... Annals of oncology 29 (7), 1554-1560, 2018 | 72 | 2018 |
| Clinical utility of circulating tumour cell androgen receptor splice variant-7 status in metastatic castration-resistant prostate cancer A Sharp, JC Welti, MBK Lambros, D Dolling, DN Rodrigues, L Pope, ... European urology 76 (5), 676-685, 2019 | 71 | 2019 |
| Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study UK Collaborative Group on HIV Drug Resistance Bmj 345, 2012 | 71 | 2012 |
